We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-0.72%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$108M
AUM Growth
-$14.5M
Cap. Flow
-$5.64M
Cap. Flow %
-5.21%
Top 10 Hldgs %
67.6%
Holding
63
New
4
Increased
7
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$736K
2
XOM icon
ExxonMobil
XOM
+$681K
3
CORT icon
Corcept Therapeutics
CORT
+$657K
4
BDSX icon
Biodesix
BDSX
+$497K
5
CSTL icon
Castle Biosciences
CSTL
+$446K

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$4.8M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$1.69M
3
PXD
Pioneer Natural Resource Co.
PXD
+$998K
4
BMY icon
Bristol-Myers Squibb
BMY
+$689K
5
OVV icon
Ovintiv
OVV
+$503K

Sector Composition

Rank Sector Weight
1 Healthcare 94.57%
2 Energy 5.43%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INBX icon
51
Inhibrx
INBX
$1.26B
$171K 0.16%
+12,110
New +$189K
GOSS icon
52
Gossamer Bio
GOSS
$72M
$124K 0.12%
138,176
– –
LQDA icon
53
Liquidia Corp
LQDA
$7B
$120K 0.11%
10,000
– –
IFRX icon
54
InflaRx
IFRX
$271M
$87K 0.08%
50,000
– –
CABA icon
55
Cabaletta Bio
CABA
$460M
$74.8K 0.07%
10,000
– –
TSVT
56
DELISTED
2seventy bio
TSVT
$68.7K 0.06%
17,833
-2,000
-10% -$9.02K
VTYX
57
DELISTED
Ventyx Biosciences
VTYX
$66.5K 0.06%
28,800
– –
ZNTL icon
58
Zentalis Pharmaceuticals
ZNTL
$372M
$65.4K 0.06%
16,000
– –
OM icon
59
Outset Medical
OM
$76.6M
$38.5K 0.04%
+667
New +$32.7K
CERO
60
DELISTED
CERo Therapeutics
CERO
$3.88K ﹤0.01%
6
– –
PXD
61
DELISTED
Pioneer Natural Resource Co.
PXD
– –
-3,800
Closed -$998K
YTEN
62
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
– –
-781
Closed -$7.13K
INBX
63
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-48,448
Closed -$1.69M
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Birchview Capital held 63 positions worth $108M, down 12% from $123M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Birchview Capital withdrew a net $5.64M in Q2 2024, closing 3 positions and reducing 9 holdings. Its most notable exit was Inhibrx, Inc. Common Stock, an estimated $1.69M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Energy and Consumer Staples.

Against the trend, Birchview Capital opened a new position in ExxonMobil worth $673K.

  • Birchview Capital's largest Q2 2024 buy was ExxonMobil: 5,849 shares worth $673K.
  • Birchview Capital added most to Prothena Corp in Q2 2024, an estimated $736K increase.
  • Birchview Capital's biggest Q2 2024 reduction was Neurocrine Biosciences, cutting an estimated $4.8M.
  • Birchview Capital fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $1.69M.
  • Birchview Capital's ten largest holdings make up 68% of its $108M portfolio in Q2 2024.
  • Birchview Capital opened 4 new positions and closed 3 in Q2 2024.
  • Birchview Capital's portfolio value fell 12% quarter-over-quarter to $108M.

Based on Birchview Capital's 13F filing for Q2 2024, filed 13 Aug 2024.